GPT and metabolic dysfunction-associated steatotic liver disease: The ability of glucagon‐like peptide‐1 receptor agonists to reduce weight and lower ALT levels implies a potential role for these compounds in NAFLD/NASH treatment, and histological data are awaited from an ongoing phase 2 trial of semaglutide in biopsy‐proven NASH (NCT02970942).